ReviewFrontiers in pharmacology2022
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Cadmium inhibits hSMUG1-mediated uracil excision: quantitative analysis and mitigation byJournal of enzyme inhibition and medicinal chemistry · 2026Article
- Anti-asthmatic effects and ingredient annotation of the active fraction from Ganoderma lucidum.Journal of natural medicines · 2026Article
- Phytochemical Profiling and Bioactivity Evaluation ofMetabolites · 2026Article
- Immunomodulatory Effects ofCurrent issues in molecular biology · 2025Review
- CRISPR/Cas9-mediated genome editing in Ganoderma lucidum: recent advances and biotechnological opportunities.World journal of microbiology & biotechnology · 2025Review
- Structure-function insights of natural Ganoderma polysaccharides: advances in biosynthesis and functional food applications.Natural products and bioprospecting · 2025Review
- From functional foods to immunotherapeutic agents: mechanistic insights into medicinal mushroom bioactives in chronic inflammation management.Frontiers in nutrition · 2025Review
- Unveiling triterpenoid superiority in a newly developedFrontiers in nutrition · 2025Article
- Tibetan medicine Pa Zhu Wan ameliorates carbon tetrachloride-induced liver fibrosis in rats by regulating the TGF-β-Smad2/3 and IL-6/JAK2/STAT3 signaling pathways.Frontiers in pharmacology · 2025Article
- Article
- Bioactivities and industrial standardization status ofHeliyon · 2024Review
- Nutritional Support for Liver Diseases.Nutrients · 2023Review
- Review
- Spore Oil-Functionalized Selenium Nanoparticles Protect Pancreatic Beta Cells from Palmitic Acid-Induced Apoptosis via Inhibition of Oxidative Stress-Mediated Apoptotic Pathways.Antioxidants (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.